Chong Kun Dang Pharmaceutical Corp
KRX:185750
Chong Kun Dang Pharmaceutical Corp
KRX:185750
Price:
82 900
KRW
2.98%
Market Closed
Market Cap:
1.1T
KRW
Income Statement
Earnings Waterfall
Chong Kun Dang Pharmaceutical Corp
Chong Kun Dang Pharmaceutical Corp
|
Revenue
|
1.6T
KRW
|
|
Cost of Revenue
|
-1.1T
KRW
|
|
Gross Profit
|
532.6B
KRW
|
|
Operating Expenses
|
-433.1B
KRW
|
|
Operating Income
|
99.5B
KRW
|
|
Other Expenses
|
9.6B
KRW
|
|
Net Income
|
109.1B
KRW
|
Income Statement
Chong Kun Dang Pharmaceutical Corp
Chong Kun Dang Pharmaceutical Corp
Currency: KRW
Millions
TTM
| Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||
| Interest Expense |
4 808
|
5 610
|
6 197
|
6 847
|
7 644
|
8 339
|
8 976
|
9 271
|
9 079
|
8 797
|
8 624
|
8 319
|
|
| Revenue |
1 373 018
N/A
|
1 411 508
+3%
|
1 453 159
+3%
|
1 488 345
+2%
|
1 512 154
+2%
|
1 542 134
+2%
|
1 561 851
+1%
|
1 669 404
+7%
|
1 665 726
0%
|
1 666 522
+0%
|
1 675 678
+1%
|
1 586 431
-5%
|
|
| Gross Profit | |||||||||||||
| Cost of Revenue |
(864 886)
|
(898 595)
|
(928 525)
|
(945 705)
|
(959 333)
|
(979 522)
|
(989 778)
|
(1 007 203)
|
(1 006 471)
|
(1 010 926)
|
(1 041 077)
|
(1 053 820)
|
|
| Gross Profit |
508 132
N/A
|
512 913
+1%
|
524 634
+2%
|
542 639
+3%
|
552 821
+2%
|
562 612
+2%
|
572 073
+2%
|
662 202
+16%
|
659 254
0%
|
655 597
-1%
|
634 601
-3%
|
532 611
-16%
|
|
| Operating Income | |||||||||||||
| Operating Expenses |
(410 196)
|
(419 681)
|
(428 250)
|
(432 733)
|
(440 387)
|
(432 117)
|
(425 167)
|
(415 602)
|
(413 315)
|
(418 817)
|
(427 531)
|
(433 150)
|
|
| Selling, General & Administrative |
(242 827)
|
(250 797)
|
(255 388)
|
(250 320)
|
(254 763)
|
(255 910)
|
(259 895)
|
(268 423)
|
(272 210)
|
(276 098)
|
(277 183)
|
(281 035)
|
|
| Research & Development |
(162 135)
|
(163 382)
|
(167 075)
|
(176 325)
|
(175 395)
|
(165 765)
|
(154 620)
|
(140 235)
|
(134 071)
|
(135 628)
|
(142 694)
|
(143 914)
|
|
| Depreciation & Amortization |
(5 235)
|
(5 502)
|
(5 788)
|
(6 089)
|
(6 316)
|
(6 530)
|
(6 740)
|
(6 945)
|
(7 034)
|
(7 091)
|
(7 654)
|
(8 200)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
(3 912)
|
(3 912)
|
(3 912)
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
97 935
N/A
|
93 232
-5%
|
96 383
+3%
|
109 906
+14%
|
112 435
+2%
|
130 494
+16%
|
146 906
+13%
|
246 599
+68%
|
245 939
0%
|
236 780
-4%
|
207 070
-13%
|
99 462
-52%
|
|
| Pre-Tax Income | |||||||||||||
| Interest Income Expense |
(3 295)
|
(6 183)
|
(8 440)
|
(9 721)
|
(8 793)
|
(6 694)
|
(4 035)
|
(3 939)
|
(220)
|
2 805
|
4 185
|
4 525
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
(3 912)
|
0
|
0
|
0
|
604
|
(280)
|
(280)
|
(280)
|
(924)
|
|
| Gain/Loss on Disposition of Assets |
66
|
71
|
0
|
54
|
53
|
204
|
153
|
112
|
130
|
(26)
|
129
|
154
|
|
| Total Other Income |
(9 970)
|
(10 348)
|
961
|
838
|
1 030
|
1 231
|
711
|
(1 777)
|
(2 123)
|
(1 749)
|
(2 302)
|
(1 208)
|
|
| Pre-Tax Income |
84 736
N/A
|
76 772
-9%
|
88 904
+16%
|
97 165
+9%
|
104 724
+8%
|
125 236
+20%
|
143 735
+15%
|
241 598
+68%
|
243 448
+1%
|
237 530
-2%
|
208 803
-12%
|
102 009
-51%
|
|
| Net Income | |||||||||||||
| Tax Provision |
(39 624)
|
(32 411)
|
(18 062)
|
(17 187)
|
(6 151)
|
(6 044)
|
(6 515)
|
(27 996)
|
(39 263)
|
(21 469)
|
(17 312)
|
9 433
|
|
| Income from Continuing Operations |
45 112
|
44 361
|
70 842
|
79 978
|
98 573
|
119 191
|
137 220
|
213 602
|
204 184
|
216 061
|
191 491
|
111 442
|
|
| Income to Minority Interest |
(16)
|
(69)
|
(151)
|
976
|
808
|
(146)
|
(1 123)
|
(1 081)
|
(1 942)
|
(3 273)
|
(2 452)
|
(2 369)
|
|
| Net Income (Common) |
45 096
N/A
|
44 292
-2%
|
70 692
+60%
|
80 953
+15%
|
99 381
+23%
|
119 045
+20%
|
136 097
+14%
|
212 521
+56%
|
202 243
-5%
|
212 788
+5%
|
189 039
-11%
|
109 073
-42%
|
|
| EPS (Diluted) |
3 657.68
N/A
|
3 602.56
-2%
|
5 785.8
+61%
|
5 994.34
+4%
|
7 780.95
+30%
|
9 328.28
+20%
|
10 673.55
+14%
|
15 908.69
+49%
|
15 162.05
-5%
|
15 978.94
+5%
|
14 220.49
-11%
|
7 842.33
-45%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
